We can only imagine that the next Pfizer and BioNTech mRNA vaccine, this time for influenza (and RSV…and likely many, many more to come), is likely to have the same ties to morally tainted cell lines as their COVID-19 vaccine.
We hope that, at worst, the new Pfizer and BioNTech’s mRNA influenza vaccines will, like COVID-19 vaccine, utilize morally compromised cell lines only in the confirmatory lab testing phase, and not in Design & Development or Production. Regardless, this is the time for each of us make our voices heard. Please reach out in writing and/or by phone to any and all of the groups listed below to let them know that morally-acceptable vaccines, in addition to be the right thing to do, will be the most commercially successful as well!
Remember…while the Holy Father, through the CDF, and our Bishops (along with others) have been clear that while we are able to accept the currently-available COVID-19 vaccines with a clear conscience, we are also obligated to both avoid scandal and advocate for the development of vaccines that are developed in morally acceptable ways. The advocacy can take many forms, including…
- Donating to organizations that are developing such vaccines, including the JP2 Medical Research Institute
- Thanking companies that are developing morally acceptable vaccines including Sanofi Pasture (Human Life Action provides a convenient contact template for Sanofi specifically) and urging them, if they were to create future morally acceptable vaccines.
- Urging companies that are almost there with COVID-19 vaccine to switch utilize fully morally acceptable vaccine development processes in the future. You can contact Pfizer here and Moderna here.
- The USCCB has sample letters to vaccine-producing companies urging them to produce morally acceptable vaccines
- Charitably admonishing companies that are not almost there (i.e., developing very morally problematic vaccines) to change course. AstraZeneca is the company closest to getting a severely morally problematic vaccine approved and can be contacted here.